Abstract:

BACKGROUND: Recently, more and more people try to use stem cells to treat diabetes mellitus. Application of autologous bone marrow stem cells is a simplest and safest method, but no reports have addressed autologous bone marrow stem cells for type 2 diabetes mellitus. There are several reports concerning the outcomes of diabetes mellitus treatment. Thus, there is no final conclusion at present.
OBJECTIVE: To observe effectiveness of autologous bone marrow stem cells for type 2 diabetes mellitus via splenic artery transplantation, and to explore its feasibility, safety and validity.
METHODS: A total of 5 patients with acute myocardial infarction and type 2 diabetes mellitus had been enrolled at the ICU Department, Wenjiang People’s Hospital from March to July 2009. They received insulin combined with oral administration of sugar-reducing drugs, but blood sugar was not fully controlled, and then subjected to autologous bone marrow cell transplantation. ①Patients received multipoint puncturation in the bilateral posterior superior iliac spine in a prone position following local anesthesia. A total of 100-150 mL bone marrow blood was collected. This test was accomplished within 60 minutes. Bone marrow cells were harvested from bone marrow blood, washed, and then diluted using saline into mononuclear cell suspension about 20-30 mL. ②Through femoral artery intubation, 4.0 cm judkins 5 or 6F right coronary arteriography catheter was inserted into the celiac trunk. The catheter direction was regulated, and the catheter entered splenic artery. Following injection of 5-10 mL ultravist, the catheter position was determined, and bone marrow cell suspension was inserted. ③Blood glucose levels and insulin dosage were followed up at 3 and 9 months following transplantation.
RESULTS AND CONCLUSION: A total of 5 patients with coronary artery disease and type 2 diabetes mellitus received successfull transplantation and were followed up. ①During autologous bone marrow cell transplantation, no adverse reaction was detected; two cases developed abdomen fever; one case suffered from light nausea. ②Compared with pretransplantation, fasting blood glucose was reduced by 23% and 27% at 3 and 9 months after the transplantation. ③Compared with pretransplantation, daily insulin requirement was significantly reduced by 22% and 42% at 3 and 9 months after the transplantation. These results have demonstrated that selective spleen arterial transplantation of autologous bone marrow cells is safe and can decrease blood glucose level and daily insulin dose in patients with type 2 diabetes mellitus.